Howard McLeod, Center Director at Center for Precision Medicine and Functional Genomics, shared a post on LinkedIn:
“Genomic analysis provides clinically important data to forecast disease risk and drug activity. This paper assessed acquired mutations in the germline genome (CHIP), that accumulate as we age and then demonstrated that therapy for cancer, either tyrosine kinase inhibitors or radionuclides can change the trajectory of these acquired mutations.
Since CHIP is associated with risk of heart disease, stroke, and leukemia, this takes us towards more complex and hopefully more accurate outcome forecasting using genomic data.”
Title: Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer
Authors: Aslı D. Munzur, Cameron Herberts, Edmond M. Kwan, Louise Emmett, Shahneen Sandhu, James P. Buteau, Amir Iravani, Anthony M. Joshua, Roslyn J. Francis, Sze-Ting Lee, Andrew M. Scott, Andrew J. Martin, Martin R. Stockler, Alison Y. Zhang, Scott G. Williams, Cecily Q. Bernales, Gráinne Donnellan, Melissa Koudjanian, Karan Parekh, Jack V. W. Bacon, Aly Karsan, Arun A. Azad, Ian D. Davis, Michael S. Hofman, Alexander W. Wyatt
Read The Full Article
Other articles about Radioligand Therapy on OncoDaily.